Signal Management

Overview

Signal management is a core pharmacovigilance activity used to identify new or changing safety information that may indicate a previously unknown risk or a meaningful change in a known risk.

Mediature GxP Solutions Pvt. Ltd. (MGS) supports Marketing Authorization Holders, pharmaceutical companies, CROs, and other life-sciences organizations with signal detection, validation, assessment, prioritization, documentation, tracking, and follow-up activities.

Our approach integrates individual case reports, literature, aggregate data, regulatory information, known product safety profiles, clinical context, and benefit-risk considerations to support systematic and traceable signal management.

Our Signal Management Services

Signal Detection

Review of available safety information to identify potential new or changing safety concerns.

Signal Validation

Assessment of whether the available information is sufficiently credible, clinically relevant, and supported to justify further evaluation.

Signal Prioritization

Risk-based prioritization of validated signals considering factors such as seriousness, severity, frequency, preventability, affected population, exposure, and potential public-health impact.

Signal Assessment

Structured evaluation of relevant case data, literature, product information, biological plausibility, temporal relationship, alternative explanations, and other supporting evidence.

Case Series Review

Assessment of multiple relevant ICSRs to identify patterns in patient characteristics, event characteristics, latency, outcomes, dechallenge, rechallenge, and other clinical features.

Literature Review

Focused review of published medical and scientific literature relevant to the suspected safety issue.

Trend Analysis

Evaluation of case patterns, reporting frequency, seriousness, outcomes, or other relevant trends that may support further safety assessment.

Benefit-Risk Support

Support for evaluating whether new safety information may affect the existing benefit-risk profile of the product.

Signal Tracking

Maintenance of signal registers, status, source, detection date, assessment history, actions, and closure rationale.

Signal Assessment Reports

Preparation of structured reports documenting the safety issue, evidence reviewed, analysis performed, conclusions, and recommended actions.

Potential Sources of Signals

Depending on scope, MGS may support review of information from:

• Spontaneous ICSRs
• Follow-up cases
• Literature
• Clinical-study safety data
• Aggregate reports
• Regulatory authority communications
• Product complaints with safety information
• Medical inquiries
• Partner safety data
• Special-situation reports
• Periodic safety reviews
• Known-risk trends
• Other relevant internal or external safety sources

Examples of Potential Signal Scenarios

A potential signal may arise from:

• A previously unknown adverse reaction
• Increase in frequency of a known reaction
• Increase in severity of a known reaction
• New clinical characteristics of a known reaction
• New susceptible or at-risk population
• New drug interaction
• Medication error pattern
• Off-label use associated with safety concerns
• Pregnancy-related safety information
• Unexpected outcome pattern
• New information affecting an established risk

Key Signal Assessment Considerations

MGS may evaluate:

• Number and quality of cases
• Case completeness
• Seriousness
• Clinical pattern
• Time to onset
• Dose relationship
• Dechallenge
• Rechallenge
• Biological plausibility
• Alternative causes
• Concomitant medications
• Patient risk factors
• Literature evidence
• Known pharmacology
• Product-label information
• Class effects
• Exposure
• Reporting trends
• Regulatory information
• Potential public-health impact

Our Signal Management Approach

• Detect

Review available safety information to identify potential new or changing safety issues.

• Validate

Determine whether the information supports further formal evaluation.

• Prioritize

Assess urgency and importance based on potential clinical and public-health impact.

• Assess

Review cases, literature, trends, product information, biological plausibility, and other relevant evidence.

• Recommend

Document conclusions and recommend appropriate actions such as continued monitoring, additional investigation, labeling review, risk-management activity, or closure.

• Track & Close

Maintain signal status, actions, evidence, decisions, and closure rationale in a traceable manner.

Typical Deliverables

Depending on scope, MGS can provide:

• Signal detection records
• Signal tracking log
• Potential-signal assessment
• Signal validation documentation
• Signal prioritization record
• Case-series review
• Literature review
• Trend analysis
• Signal Assessment Report
• Benefit-risk assessment support
• Action tracker
• Signal closure documentation
• Periodic signal-management summary

Why Choose MGS

Integrated Safety Review

MGS combines ICSR data, literature, product information, and other safety sources within a structured signal-management process.

Clinically Focused Assessment

Signal evaluation considers medical relevance, plausibility, pattern, severity, and available evidence rather than case counts alone.

Traceable Documentation

Our approach emphasizes clear rationale, evidence, decisions, actions, and closure documentation.

Risk-Based Prioritization

Signals are evaluated according to their potential impact on patients, product safety, and public health.

Lifecycle Integration

Signal-management findings can feed into aggregate reporting, risk management, labeling assessment, SOPs, and broader benefit-risk evaluation.

Who We Support

MGS can provide Signal Management support for:

• Marketing Authorization Holders
• Pharmaceutical companies
• Biopharmaceutical organizations
• CROs
• Generic-drug companies
• Product-license partners
• Organizations establishing formal signal-management processes
• Companies requiring periodic or product-specific safety review